Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Caubel

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Clinical Drug Investigation|September 13, 2022
Reporting of COVID-19 Reinfection and Potential Role of Immunosuppressant/Immunomodulating Agents: A Cross-Sectional Observational Analysis Based on a Spontaneous Reporting DatabaseElena Beyzarov, Yan Chen, Patrick Caubel
Clinical Therapeutics|December 15, 2018
Deconstructing the Pharmacovigilance Hype CycleManfred Hauben, Robert Reynolds, Patrick Caubel
Clinical Therapeutics|July 13, 2024
A Retrospective Case Series Analysis of Pregnancy and COVID-19 Based on a Global Postmarketing COVID-19 Surveillance ProgramElena Beyzarov, Yan Chen, Patrick Caubel
Acta Obstetricia Et Gynecologica Scandinavica|August 23, 2002
Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetateOlavi Ylikorkala, Torsten Wahlström, Patrick Caubel, et al.
Maturitas|June 23, 2004
The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal womenStefan Arrenbrecht, Patrick Caubel, Patrick Garnero, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|September 13, 2003
Feto-maternal alloimmune thrombocytopenia due to HPA-5b incompatibility: a case reportRafael J M Herrero, Yvon Chitrit, Patrick Caubel, et al.
Pharmaceutical Medicine|January 15, 2020
Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry SurveyStella Stergiopoulos, Mortiz Fehrle, Patrick Caubel, et al.
Pharmaceutical Medicine|February 13, 2020
Correction to: Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry SurveyStella Stergiopoulos, Moritz Fehrle, Patrick Caubel, et al.
Clinical Therapeutics|August 8, 2022
Effects of the COVID-19 Pandemic on Pharmacovigilance Strategy, Systems, and Processes of Large, Medium, and Small Companies: An Industry SurveyPaul Beninger, Patrick Caubel, Latika Sharma, et al.
Pharmacoepidemiology and Drug Safety|December 12, 2019
Trial designs using real-world data: The changing landscape of the regulatory approval processElodie Baumfeld Andre, Robert Reynolds, Patrick Caubel, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Clinical Drug Investigation|September 13, 2022
Reporting of COVID-19 Reinfection and Potential Role of Immunosuppressant/Immunomodulating Agents: A Cross-Sectional Observational Analysis Based on a Spontaneous Reporting DatabaseElena Beyzarov, Yan Chen, Patrick Caubel
Clinical Therapeutics|December 15, 2018
Deconstructing the Pharmacovigilance Hype CycleManfred Hauben, Robert Reynolds, Patrick Caubel
Clinical Therapeutics|July 13, 2024
A Retrospective Case Series Analysis of Pregnancy and COVID-19 Based on a Global Postmarketing COVID-19 Surveillance ProgramElena Beyzarov, Yan Chen, Patrick Caubel
Acta Obstetricia Et Gynecologica Scandinavica|August 23, 2002
Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetateOlavi Ylikorkala, Torsten Wahlström, Patrick Caubel, et al.
Maturitas|June 23, 2004
The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal womenStefan Arrenbrecht, Patrick Caubel, Patrick Garnero, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|September 13, 2003
Feto-maternal alloimmune thrombocytopenia due to HPA-5b incompatibility: a case reportRafael J M Herrero, Yvon Chitrit, Patrick Caubel, et al.
Pharmaceutical Medicine|January 15, 2020
Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry SurveyStella Stergiopoulos, Mortiz Fehrle, Patrick Caubel, et al.
Pharmaceutical Medicine|February 13, 2020
Correction to: Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry SurveyStella Stergiopoulos, Moritz Fehrle, Patrick Caubel, et al.
Clinical Therapeutics|August 8, 2022
Effects of the COVID-19 Pandemic on Pharmacovigilance Strategy, Systems, and Processes of Large, Medium, and Small Companies: An Industry SurveyPaul Beninger, Patrick Caubel, Latika Sharma, et al.
Pharmacoepidemiology and Drug Safety|December 12, 2019
Trial designs using real-world data: The changing landscape of the regulatory approval processElodie Baumfeld Andre, Robert Reynolds, Patrick Caubel, et al.
Pageof 2